Analyze Publications Database

Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival

Jin H, Yang R, Ross J, Fong S, Carano R, Totpal K, Lawrence D, Zheng Z, Koeppen H, Stern H, Schwall R, Ashkenazi A. Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res. December 2008;14(23):7733-7740.

Full Text – Open Access

Publication Date
December 2008

How Analyze was Used
“Image data were evaluated with the aid of Analyze (AnalyzeDirect, Inc.), an image analysis software package.”

Keywords
Animals
Antibodies, Monoclonal/administration & dosage
Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Apoptosis/drug effects
Carboplatin/administration & dosage
Carcinoma, Non-Small-Cell Lung/drug therapy
Cell Line, Tumor
Cell Proliferation/drug effects
Female
Humans
Immunoblotting
In Situ Nick-End Labeling
Lung Neoplasms/drug therapy
Mice
Mice, Nude
Paclitaxel/administration & dosage
Receptors, TNF-Related Apoptosis-Inducing Ligand/agonists/drug effects
Xenograft Model Antitumor Assays

Author Affiliation(s)
Department of Translational Oncology, Genentech, Inc., South San Francisco, CA, US. (HJ, RY, SF, KT, ZZ, RS)

Department of Tumor Biology and Angiogenesis, Genentech, Inc., South San Francisco, CA, US. (JR, RC)

Department of Molecular Oncology, Genentech, Inc., South San Francisco, CA, US. (DL, AA)

Department of Pathology, Genentech, Inc., South San Francisco, CA, US. (HK, HS)

ID# 1523

Tags: , , , , , , , , , , , , , , , , ,